Interview

CEO Mike Kujak Interviewed by Medtech Insight

August 6, 2024

doctor showing patient a model of the anatomy of the prostate

In a recent exclusive interview with Citeline Commercial’s Medtech Insight, Mike Kujak, CEO of Francis Medical, revealed the latest developments regarding Vanquish—our revolutionary advancement for treating prostate cancer with water vapor therapy. Kujak’s insights offer a glimpse into how this innovative device is set to redefine standards in prostate cancer treatment.

Medtech Insight Article: Vanquishing Prostate Cancer Without Debilitating Side Effects – Francis Medical CEO On Water Vapor Ablation

More on Mike on our Leadership Page

Share this post

Recent Posts

Francis Medical Announces First Commercial Vanquish® Procedure to Ablate Prostate Tissue in the Midwest

April 21st, 2026|

Minneapolis [April 21, 2026] – Francis Medical, Inc., a privately held medical device company based out of Maple Grove, MN, today announced that Aaron Milbank, MD. of Minnesota Urology has successfully completed the first commercial procedure in the Midwest using the Vanquish® Water Vapor Ablation System, a minimally invasive technology designed to ablate targeted prostate tissue.

Francis Medical Announces Further Commercial Expansion of Vanquish® Water Vapor Ablation with First Commercial Procedures to Ablate Targeted Prostate Tissue in the Southeast

April 16th, 2026|

Minneapolis, MN [April 16, 2026] – Francis Medical, Inc., a privately held medical device company, today announced the continued expansion of its U.S. commercial launch with the first commercial procedures performed using the Vanquish® Water Vapor Ablation System in the Southeast, a minimally invasive technology designed to ablate targeted prostate tissue.

Francis Medical Announces First Commercial Vanquish® Procedure on the East Coast for Prostate Tissue Ablation

March 25th, 2026|

Minneapolis, MN [March. 25, 2026] – Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical study) procedure on the East Coast using the Vanquish® Water Vapor Ablation System, a minimally invasive technology designed to ablate targeted prostate tissue while potentially helping to preserve urinary and sexual function.